Ultromics

Ultromics’ AI-powered echocardiography solutions have received multiple FDA clearances and CE marks. Their flagship product line—EchoGo—has demonstrated high sensitivity and specificity for detecting HFpEF and cardiac amyloidosis in published studies. The company’s technology has been validated in over twenty studies and adopted at more than fifty global sites.

For example:

• HFpEF detection by AI achieved ~90% sensitivity and ~86% specificity.
• Cardiac amyloidosis detection achieved ~84.5% sensitivity and ~89.7% specificity.

The company’s products are reimbursed under specific Medicare codes in the US.

Key partnerships include Mayo Clinic, FNIH, ASE, Northwestern Medicine, NHS UK; collaborations with Pfizer and Janssen Biotech have also been reported.

Over $57 million raised to date; Series B round closed at $33 million in August 2021.